GLP-1 Receptor Agonists to be Evaluated for Enhanced Rectal Cancer Response and Survival
Background
Locally advanced rectal cancer (LARC) management often relies on total neoadjuvant therapy (TNT), which combines chemotherapy and radiotherapy before surgery. While effective, outcomes can vary, and metabolic factors like obesity are increasingly recognized as influencing cancer progression and treatment response. Preclinical studies suggest that GLP-1 receptor agonists (GLP-1RAs), known for their weight loss and metabolic benefits, might also improve anti-tumor responses, particularly in obesity-associated cancers. This trial explores if integrating a GLP-1RA can bridge this gap, potentially enhancing TNT efficacy in high-BMI rectal cancer patients.
Study Design
This clinical trial will evaluate the impact of adding a GLP-1 receptor agonist drug to standard Total Neoadjuvant Therapy (TNT) in rectal cancer patients with an increased BMI. Patients will be randomized into two arms: one receiving the GLP-1 receptor agonist drug during TNT, and a control arm receiving TNT alone. Body weight will be measured at three time points: baseline (prior to any treatment), pre-TNT (4 weeks after semaglutide initiation for the intervention arm), and post-TNT (within 7 days of completion). The study will compare weight loss, response rates to chemoradiotherapy, and long-term survival outcomes between the two groups.
Results
This abstract describes the protocol for a clinical trial, and as such, no results are presented yet. The study aims to determine if adding a GLP-1 receptor agonist to Total Neoadjuvant Therapy (TNT) impacts several key outcomes in rectal cancer patients with high BMI. The primary objectives are to assess the drug's influence on weight loss, response rates to chemoradiotherapy, and long-term survival outcomes, including cancer recurrence.
The trial specifically aims to determine if the GLP-1 receptor agonist increases weight loss in rectal cancer patients with a high BMI, improves their response rates to chemotherapy and radiotherapy, and ultimately enhances survival outcomes while reducing cancer recurrence. The study will compare patients receiving the GLP-1 receptor agonist plus
TNTagainst a control group receivingTNTalone, with body weight measured at baseline, pre-TNT(4 weeks after drug initiation for the intervention arm), and post-TNT.
Key Findings
- Trial aims to assess if GLP-1RAs increase weight loss in rectal cancer patients with high BMI.
- Trial aims to determine if GLP-1RAs improve response rates to chemotherapy and radiotherapy.
- Trial aims to evaluate if GLP-1RAs improve survival outcomes and reduce cancer recurrence.
- Compares GLP-1RA + TNT vs. TNT alone in rectal cancer patients.
Why It Matters
If this trial demonstrates improved outcomes, it could significantly alter the standard of care for rectal cancer patients with elevated BMI, integrating metabolic management directly into oncology protocols. GLP-1 receptor agonists are already widely used for weight management and metabolic health; a positive finding here would expand their clinical utility into a novel oncological indication. Clinicians might consider prescribing GLP-1RAs concurrently with Total Neoadjuvant Therapy to enhance treatment efficacy and patient prognosis. This could lead to a new protocol for improving both cancer response and long-term survival, moving beyond just tumor-centric treatments to a more holistic approach addressing patient metabolism.
rectal-cancer
glp-1-agonist
semaglutide
neoadjuvant-therapy
obesity
clinical-trial